RE:RE:May 11 date of ownershipI have a lot of shares and honestly I'm waiting to see what happens in the next 3-4 weeks. I agree that a change in CEO would be a set back but on the other hand Tripp has had months/years planning for the roll out and partnerships. Wasn't it said the Care Oncology deal was in discussions for over a year. Didn't the prospectus have millions set aside for marketing?
Now I understand CoVid has changed the way many go to business, but there are still so many ways to market during these CoVid times and get the word out on Aristotle. So far its been too quiet.
Bottom line is if Tripp can't execute the business/marketing side, the board with Harry, Rory and others will find someone who can.
Maybe he would be better as a CSO and not CEO. He has a couple more months to provide shock and awe but if we don't see something in the next 3-4 weeks I think a message is going to be sent.
Liked2Think wrote: The fact this hasnt been able to tick upwards a bit has me worried. Not much volume though so easy to manipulate. Just seems like a huge mountain to regain to where we were now.
Confidence being tested but I think your right. Either some good results come out or some added interest or Tripp may be in trouble. hard to say cause the big holders usually dont like a leader change but they might be just as chokec as us normal investors now with the aristotle release disaster that it was.
Not that my votes really matters but as it sits right now he doesnt have my vote. I hope he can change my mind by then though as I think changing ceo's would just set us back further than the terrible rollout did.